MarketPulse

biotech stocks

10 articles
The Motley FoolThe Motley Fool··Howard Smith

Compass Pathways Surges 40% on White House Push for Psychedelic Drug Approvals

Compass Pathways stock surges 40% following White House Executive Order accelerating FDA approval of its COMP360 psychedelic therapy for treatment-resistant depression.
CMPSFDA approvaltreatment-resistant depression
The Motley FoolThe Motley Fool··Matthew Benjamin

Trump's Psychedelic Fast-Track Order Opens New Frontier for FDA Approvals

Trump executive order accelerates psychedelic drug approvals from 6-10 months to 1-2 months, allocates $50M for research, benefiting biotech companies.
DFTXCMPStreatment-resistant depressionmental health
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Two Biotech Stocks Poised to Outpace Summit Therapeutics Amid FDA Uncertainty

Summit Therapeutics faces FDA decision on ivonescimab by November 2026 amid efficacy concerns, while Axsome and Madrigal positioned for outperformance.
AXSMMDGLSMMTregulatory riskFDA approval
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Eli Lilly Edges Vertex as Superior Growth Pick Amid GLP-1 Boom

Eli Lilly ($LLY) outpaces Vertex ($VERX) as superior growth stock pick with Zepbound dominance in booming weight-loss market and stronger financials at comparable valuations.
LLYVRTXcystic fibrosispharmaceutical growth
Investing.comInvesting.com··David Wagner

Moderna's $2.25B Settlement Clears Patent Cloud as Biotech Sector Eyes Deep Value Opportunities

Moderna settles $2.25B patent dispute, surges 15.99%. Analysis identifies 9 biotech stocks trading 27-65% below fair value with 31-251% upside potential.
MRNAROIVABUSfair valueundervalued
The Motley FoolThe Motley Fool··Adria Cimino

Two Biotech Leaders Poised for Growth in 2026: REGN and VERX

Regeneron and Vertex Pharmaceuticals emerge as compelling 2026 biotech investments, with REGN valued at 17x and VERX at 24x forward earnings, offering growth and stability respectively.
VRTXREGNpharmaceutical growthinvestment recommendation
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Vertex Over CRISPR: Why Profitable Gene-Editing Beats Pipeline Dreams

Vertex Pharmaceuticals offers profitable gene-editing exposure versus CRISPR's pipeline-dependent model. Casgevy's slow adoption and high costs make Vertex's diversified, profitable business more attractive for risk-averse investors despite lower upside potential.
VRTXCRSPclinical trialspipeline candidates
BenzingaBenzinga··Rishabh Mishra

US Stock Futures Tumble as Iran Crisis Rattles Markets; Tech Stocks in Focus

U.S. stock futures fell on Iran tensions, while $HKD surged 20% on earnings and $AARD crashed 53% after trial pause.
SPYQQQALBTMDBAARD+2market volatilitystock market decline
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Pfizer's Boring Appeal: Why Blue-Chip Stability Beats Biotech Hype

Pfizer's reasonable valuation, robust pipeline, and 6.4% dividend yield offer disciplined returns versus speculative biotech like Regencell, whose 21,000% surge lacks fundamental justification.
PFERGCstock valuationclinical trials
The Motley FoolThe Motley Fool··Adria Cimino

CRISPR Therapeutics Poised for Growth on Casgevy Momentum and Pipeline Expansion

CRISPR Therapeutics eyes growth from Casgevy commercialization and pipeline expansion. FDA-approved gene therapy generates revenue while multiple clinical programs advance toward 2026 milestones.
VRTXCRSPFDA approvalclinical trials